CONTEXT: Treatment of pituitary gigantism is complex and the results are usually unsatisfactory. OBJECTIVE: The objective of the study was to describe the results of therapy of three children with pituitary gigantism by a GH receptor antagonist, pegvisomant. DESIGN: This was a descriptive case series of up to 3.5 yr duration. SETTING: The study was conducted at a university hospital. PATIENTS: Patients included three children (one female, two males) with pituitary gigantism whose GH hypersecretion was incompletely controlled by surgery, somatostatin analog, and dopamine agonist. INTERVENTION: The intervention was administration of pegvisomant. MAIN OUTCOME MEASURES: Plasma IGF-I and growth velocity were measured. RESULTS: In all three children, pegvisomant rapidly decreased plasma IGF-I concentrations. Growth velocity declined to subnormal or normal values. Statural growth fell into lower growth percentiles and acromegalic features resolved. Pituitary tumor size did not change in two children but increased in one boy despite concomitant therapy with a somatostatin analog. CONCLUSIONS: Pegvisomant may be an effective modality for the therapy of pituitary gigantism in children. Titration of the dose is necessary for optimal efficacy, and regular surveillance of tumor size is mandatory.
CONTEXT: Treatment of pituitary gigantism is complex and the results are usually unsatisfactory. OBJECTIVE: The objective of the study was to describe the results of therapy of three children with pituitary gigantism by a GH receptor antagonist, pegvisomant. DESIGN: This was a descriptive case series of up to 3.5 yr duration. SETTING: The study was conducted at a university hospital. PATIENTS: Patients included three children (one female, two males) with pituitary gigantism whose GH hypersecretion was incompletely controlled by surgery, somatostatin analog, and dopamine agonist. INTERVENTION: The intervention was administration of pegvisomant. MAIN OUTCOME MEASURES: Plasma IGF-I and growth velocity were measured. RESULTS: In all three children, pegvisomant rapidly decreased plasma IGF-I concentrations. Growth velocity declined to subnormal or normal values. Statural growth fell into lower growth percentiles and acromegalic features resolved. Pituitary tumor size did not change in two children but increased in one boy despite concomitant therapy with a somatostatin analog. CONCLUSIONS:Pegvisomant may be an effective modality for the therapy of pituitary gigantism in children. Titration of the dose is necessary for optimal efficacy, and regular surveillance of tumor size is mandatory.
Authors: P J Trainer; W M Drake; L Katznelson; P U Freda; V Herman-Bonert; A J van der Lely; E V Dimaraki; P M Stewart; K E Friend; M L Vance; G M Besser; J A Scarlett; M O Thorner; C Parkinson; A Klibanski; J S Powell; A L Barkan; M C Sheppard; M Malsonado; D R Rose; D R Clemmons; G Johannsson; B A Bengtsson; S Stavrou; D L Kleinberg; D M Cook; L S Phillips; M Bidlingmaier; C J Strasburger; S Hackett; K Zib; W F Bennett; R J Davis Journal: N Engl J Med Date: 2000-04-20 Impact factor: 91.245
Authors: Liliya Rostomyan; Adrian F Daly; Patrick Petrossians; Emil Nachev; Anurag R Lila; Anne-Lise Lecoq; Beatriz Lecumberri; Giampaolo Trivellin; Roberto Salvatori; Andreas G Moraitis; Ian Holdaway; Dianne J Kranenburg-van Klaveren; Maria Chiara Zatelli; Nuria Palacios; Cecile Nozieres; Margaret Zacharin; Tapani Ebeling; Marja Ojaniemi; Liudmila Rozhinskaya; Elisa Verrua; Marie-Lise Jaffrain-Rea; Silvia Filipponi; Daria Gusakova; Vyacheslav Pronin; Jerome Bertherat; Zhanna Belaya; Irena Ilovayskaya; Mona Sahnoun-Fathallah; Caroline Sievers; Gunter K Stalla; Emilie Castermans; Jean-Hubert Caberg; Ekaterina Sorkina; Renata Simona Auriemma; Sachin Mittal; Maria Kareva; Philippe A Lysy; Philippe Emy; Ernesto De Menis; Catherine S Choong; Giovanna Mantovani; Vincent Bours; Wouter De Herder; Thierry Brue; Anne Barlier; Sebastian J C M M Neggers; Sabina Zacharieva; Philippe Chanson; Nalini Samir Shah; Constantine A Stratakis; Luciana A Naves; Albert Beckers Journal: Endocr Relat Cancer Date: 2015-07-17 Impact factor: 5.678
Authors: Albert Beckers; Maya Beth Lodish; Giampaolo Trivellin; Liliya Rostomyan; Misu Lee; Fabio R Faucz; Bo Yuan; Catherine S Choong; Jean-Hubert Caberg; Elisa Verrua; Luciana Ansaneli Naves; Tim D Cheetham; Jacques Young; Philippe A Lysy; Patrick Petrossians; Andrew Cotterill; Nalini Samir Shah; Daniel Metzger; Emilie Castermans; Maria Rosaria Ambrosio; Chiara Villa; Natalia Strebkova; Nadia Mazerkina; Stéphan Gaillard; Gustavo Barcelos Barra; Luis Augusto Casulari; Sebastian J Neggers; Roberto Salvatori; Marie-Lise Jaffrain-Rea; Margaret Zacharin; Beatriz Lecumberri Santamaria; Sabina Zacharieva; Ee Mun Lim; Giovanna Mantovani; Maria Chaira Zatelli; Michael T Collins; Jean-François Bonneville; Martha Quezado; Prashant Chittiboina; Edward H Oldfield; Vincent Bours; Pengfei Liu; Wouter W de Herder; Natalia Pellegata; James R Lupski; Adrian F Daly; Constantine A Stratakis Journal: Endocr Relat Cancer Date: 2015-02-24 Impact factor: 5.678
Authors: Ericka B Trarbach; Giampaolo Trivellin; Isabella P P Grande; Felipe H G Duarte; Alexander A L Jorge; Felipe Barjud Pereira do Nascimento; Heraldo M Garmes; Marcia Nery; Berenice B Mendonca; Constantine A Stratakis; Marcello D Bronstein; Raquel S Jallad Journal: Pituitary Date: 2020-11-06 Impact factor: 4.107
Authors: Feng Liu; Fei Sun; Jun Hong Xia; Jian Li; Gui Hong Fu; Grace Lin; Rong Jian Tu; Zi Yi Wan; Delia Quek; Gen Hua Yue Journal: Sci Rep Date: 2014-12-01 Impact factor: 4.379